by websmart | Mar 18, 2026 | General, Oncology
### Summary: Engineered CD40 Agonist Antibody Induces Systemic Tumor Regression in Phase 1 Trial A groundbreaking phase 1 clinical trial has demonstrated the potential of an engineered CD40 agonist antibody, 2141-V11, to elicit robust systemic anti-tumor responses...
by websmart | Mar 18, 2026 | General
### Summary: Ketogenic Diet Enhances Exercise Benefits in Hyperglycemic Models A recent study published in *Nature Communications* on February 25, led by exercise medicine researcher Sarah Lessard from the Fralin Biomedical Research Institute at Virginia Tech,...
by websmart | Mar 18, 2026 | General
### Accuracy of Allergy Forecasts: Implications for Clinical Practice Allergy forecasts, commonly available on websites and apps, aim to help patients manage symptoms by predicting pollen levels, but their reliability is often questionable. Pollen counts, as reported...
by websmart | Mar 18, 2026 | General
### Summary: Key Implications of the Stryker Cyberattack for Clinical Practice In a recent cyberattack on Stryker Corporation, attributed to pro-Iran hackers and reported on March 11, 2026, the company’s internal Microsoft environment was compromised, leading to...
by websmart | Mar 18, 2026 | Diabetes, General
### Summary: Discovery of LRG1 as a Key Trigger in Diabetic Retinopathy Researchers at University College London (UCL) have identified leucine-rich alpha-2-glycoprotein 1 (LRG1) as a pivotal protein initiating early retinal damage in diabetic retinopathy, a leading...
